BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 29765138)

  • 1. Does genomic sequencing early in the diagnostic trajectory make a difference? A follow-up study of clinical outcomes and cost-effectiveness.
    Stark Z; Schofield D; Martyn M; Rynehart L; Shrestha R; Alam K; Lunke S; Tan TY; Gaff CL; White SM
    Genet Med; 2019 Jan; 21(1):173-180. PubMed ID: 29765138
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term economic impacts of exome sequencing for suspected monogenic disorders: diagnosis, management, and reproductive outcomes.
    Schofield D; Rynehart L; Shresthra R; White SM; Stark Z
    Genet Med; 2019 Nov; 21(11):2586-2593. PubMed ID: 31110331
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Whole-exome sequencing reanalysis at 12 months boosts diagnosis and is cost-effective when applied early in Mendelian disorders.
    Ewans LJ; Schofield D; Shrestha R; Zhu Y; Gayevskiy V; Ying K; Walsh C; Lee E; Kirk EP; Colley A; Ellaway C; Turner A; Mowat D; Worgan L; Freckmann ML; Lipke M; Sachdev R; Miller D; Field M; Dinger ME; Buckley MF; Cowley MJ; Roscioli T
    Genet Med; 2018 Dec; 20(12):1564-1574. PubMed ID: 29595814
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Whole exome sequencing in neurogenetic odysseys: An effective, cost- and time-saving diagnostic approach.
    Córdoba M; Rodriguez-Quiroga SA; Vega PA; Salinas V; Perez-Maturo J; Amartino H; Vásquez-Dusefante C; Medina N; González-Morón D; Kauffman MA
    PLoS One; 2018; 13(2):e0191228. PubMed ID: 29389947
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reanalysis of whole-exome sequencing (WES) data of children with neurodevelopmental disorders in a standard patient care context.
    van Slobbe M; van Haeringen A; Vissers LELM; Bijlsma EK; Rutten JW; Suerink M; Nibbeling EAR; Ruivenkamp CAL; Koene S
    Eur J Pediatr; 2024 Jan; 183(1):345-355. PubMed ID: 37889289
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Whole exome and genome sequencing in mendelian disorders: a diagnostic and health economic analysis.
    Ewans LJ; Minoche AE; Schofield D; Shrestha R; Puttick C; Zhu Y; Drew A; Gayevskiy V; Elakis G; Walsh C; Adès LC; Colley A; Ellaway C; Evans CA; Freckmann ML; Goodwin L; Hackett A; Kamien B; Kirk EP; Lipke M; Mowat D; Palmer E; Rajagopalan S; Ronan A; Sachdev R; Stevenson W; Turner A; Wilson M; Worgan L; Morel-Kopp MC; Field M; Buckley MF; Cowley MJ; Dinger ME; Roscioli T
    Eur J Hum Genet; 2022 Oct; 30(10):1121-1131. PubMed ID: 35970915
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Positioning whole exome sequencing in the diagnostic pathway for rare disease to optimise utility: a protocol for an observational cohort study and an economic evaluation.
    Hayeems RZ; Bernier F; Boycott KM; Hartley T; Michaels-Igbokwe C; Marshall DA
    BMJ Open; 2022 Oct; 12(10):e061468. PubMed ID: 36216418
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness of whole-exome sequencing and costs of the traditional diagnostic trajectory in children with intellectual disability.
    Monroe GR; Frederix GW; Savelberg SM; de Vries TI; Duran KJ; van der Smagt JJ; Terhal PA; van Hasselt PM; Kroes HY; Verhoeven-Duif NM; Nijman IJ; Carbo EC; van Gassen KL; Knoers NV; Hövels AM; van Haelst MM; Visser G; van Haaften G
    Genet Med; 2016 Sep; 18(9):949-56. PubMed ID: 26845106
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diagnostic Impact and Cost-effectiveness of Whole-Exome Sequencing for Ambulant Children With Suspected Monogenic Conditions.
    Tan TY; Dillon OJ; Stark Z; Schofield D; Alam K; Shrestha R; Chong B; Phelan D; Brett GR; Creed E; Jarmolowicz A; Yap P; Walsh M; Downie L; Amor DJ; Savarirayan R; McGillivray G; Yeung A; Peters H; Robertson SJ; Robinson AJ; Macciocca I; Sadedin S; Bell K; Oshlack A; Georgeson P; Thorne N; Gaff C; White SM
    JAMA Pediatr; 2017 Sep; 171(9):855-862. PubMed ID: 28759686
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exome Sequencing for Isolated Congenital Hearing Loss: A Cost-Effectiveness Analysis.
    Downie L; Amor DJ; Halliday J; Lewis S; Martyn M; Goranitis I
    Laryngoscope; 2021 Jul; 131(7):E2371-E2377. PubMed ID: 33382469
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Integrating exome sequencing into a diagnostic pathway for epileptic encephalopathy: Evidence of clinical utility and cost effectiveness.
    Palmer EE; Schofield D; Shrestha R; Kandula T; Macintosh R; Lawson JA; Andrews I; Sampaio H; Johnson AM; Farrar MA; Cardamone M; Mowat D; Elakis G; Lo W; Zhu Y; Ying K; Morris P; Tao J; Dias KR; Buckley M; Dinger ME; Cowley MJ; Roscioli T; Kirk EP; Bye A; Sachdev RK
    Mol Genet Genomic Med; 2018 Mar; 6(2):186-199. PubMed ID: 29314763
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Not the End of the Odyssey: Parental Perceptions of Whole Exome Sequencing (WES) in Pediatric Undiagnosed Disorders.
    Rosell AM; Pena LD; Schoch K; Spillmann R; Sullivan J; Hooper SR; Jiang YH; Mathey-Andrews N; Goldstein DB; Shashi V
    J Genet Couns; 2016 Oct; 25(5):1019-31. PubMed ID: 26868367
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A head-to-head evaluation of the diagnostic efficacy and costs of trio versus singleton exome sequencing analysis.
    Tan TY; Lunke S; Chong B; Phelan D; Fanjul-Fernandez M; Marum JE; Kumar VS; Stark Z; Yeung A; Brown NJ; Stutterd C; Delatycki MB; Sadedin S; Martyn M; Goranitis I; Thorne N; Gaff CL; White SM
    Eur J Hum Genet; 2019 Dec; 27(12):1791-1799. PubMed ID: 31320747
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of exome and genome sequencing for children with rare and undiagnosed conditions.
    Lavelle TA; Feng X; Keisler M; Cohen JT; Neumann PJ; Prichard D; Schroeder BE; Salyakina D; Espinal PS; Weidner SB; Maron JL
    Genet Med; 2022 Jun; 24(6):1349-1361. PubMed ID: 35396982
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of whole-exome sequencing in progressive neurological disorders of children.
    Aaltio J; Hyttinen V; Kortelainen M; Frederix GWJ; Lönnqvist T; Suomalainen A; Isohanni P
    Eur J Paediatr Neurol; 2022 Jan; 36():30-36. PubMed ID: 34852981
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prospective comparison of the cost-effectiveness of clinical whole-exome sequencing with that of usual care overwhelmingly supports early use and reimbursement.
    Stark Z; Schofield D; Alam K; Wilson W; Mupfeki N; Macciocca I; Shrestha R; White SM; Gaff C
    Genet Med; 2017 Aug; 19(8):867-874. PubMed ID: 28125081
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reduced resource utilization with early use of next-generation sequencing in rare genetic diseases in an Asian cohort.
    Nazeha N; Koh AL; Kam S; Lim JY; Goh DLM; Jamuar SS; Graves N
    Am J Med Genet A; 2022 Dec; 188(12):3482-3491. PubMed ID: 36156406
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Whole-exome sequencing in intellectual disability; cost before and after a diagnosis.
    Vrijenhoek T; Middelburg EM; Monroe GR; van Gassen KLI; Geenen JW; Hövels AM; Knoers NV; van Amstel HKP; Frederix GWJ
    Eur J Hum Genet; 2018 Nov; 26(11):1566-1571. PubMed ID: 29959382
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A population-based cost-effectiveness study of early genetic testing in severe epilepsies of infancy.
    Howell KB; Eggers S; Dalziel K; Riseley J; Mandelstam S; Myers CT; McMahon JM; Schneider A; Carvill GL; Mefford HC; ; Scheffer IE; Harvey AS
    Epilepsia; 2018 Jun; 59(6):1177-1187. PubMed ID: 29750358
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Meeting the challenges of implementing rapid genomic testing in acute pediatric care.
    Stark Z; Lunke S; Brett GR; Tan NB; Stapleton R; Kumble S; Yeung A; Phelan DG; Chong B; Fanjul-Fernandez M; Marum JE; Hunter M; Jarmolowicz A; Prawer Y; Riseley JR; Regan M; Elliott J; Martyn M; Best S; Tan TY; Gaff CL; White SM;
    Genet Med; 2018 Dec; 20(12):1554-1563. PubMed ID: 29543227
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.